Ola N.
- Country
- Sweden
- Department
- Institutionen för Kvinnor och Barns Hälsa
Research Overview
- Phase 2 Multicenter Double-Blind Randomized Placebo-Controlled Trial of TransCon CNP in Infants with Achondroplasia Evaluating Safety, Tolerability, and Efficacy
- Efficacy and Safety Evaluation of ALXN1850 in Pediatric Patients with Hypophosphatasia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Evaluation of INZ-701 for Efficacy and Safety in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Data & Insights
Has run more than one trial at 7 of 30 partner sites.
Specializations
Rare Genetic Disorders
The investigator specializes in treating hypophosphatasia (HPP), a rare inherited metabolic disorder affecting bone development and mineralization.
- Bone Mineralization Disorders
- Metabolic Bone Disease
- Pediatric Skeletal Disorders
Their research focuses on innovative therapeutic approaches for managing bone mineralization defects in pediatric populations.
Growth Disorders
The investigator conducts research in achondroplasia, the most common form of skeletal dysplasia causing dwarfism in children and adolescents.
- Skeletal Dysplasia
- Growth Development
- Pediatric Endocrinology
Their work encompasses evaluating novel therapeutic options for improving growth outcomes in children with skeletal growth disorders.
Metabolic Disorders
The investigator studies ENPP1 Deficiency, a rare genetic condition affecting cardiovascular health and tissue calcification.
- Cardiovascular Complications
- Arterial Calcification
- Enzyme Replacement Therapy
Their research addresses cardiac dysfunction and arterial calcification in pediatric patients with metabolic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.